

产品别名: Eslicarbazepine acetate; 醋酸艾司利卡西平; BIA 2-093

Description	Eslicarbazepine acetate, an antiepileptic drug, is a dual a dual Inhibitor of β -Secretase and voltage-gated sodium channel.																
In Vivo	Eslicarbazepine acetate is an antiepileptic drug. It is a prodrug which is activated to eslicarbazepine (S-licarbazepine), an active metabolite of oxcarbazepine. Eslicarbazepine acetate is a prodrug for (S)-(+)-licarbazepine, the major active metabolite of oxcarbazepine. Its mechanism of action is therefore identical to that of oxcarbazepine. Eslicarbazepine acetate may not produce as high peak levels of (S)-(+)-licarbazepine immediately after dosing as does oxcarbazepine which could theoretically improve tolerability[1].																
Solvent&Solubility	In Vitro: DMSO : ≥ 100 mg/mL (337.47 mM) * " \geq " means soluble, but saturation unknown.																
	Preparing Stock Solutions	<div>Solvent Mass Concentration</div>	1 mg	5 mg	10 mg	1 mM	3.3747 mL	16.8736 mL	33.7473 mL	5 mM	0.6749 mL	3.3747 mL	6.7495 mL	10 mM	0.3375 mL	1.6874 mL	3.3747 mL
		Preparing Stock Solutions	<div>Solvent Mass Concentration</div>	1 mg	5 mg	10 mg											
			1 mM	3.3747 mL	16.8736 mL	33.7473 mL											
			5 mM	0.6749 mL	3.3747 mL	6.7495 mL											
	10 mM		0.3375 mL	1.6874 mL	3.3747 mL												
	*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液，一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。																
	储备液的保存方式和期限 -80℃, 6 months; -20℃, 1 month。 -80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。																
	In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶																
	1.请依序添加每种溶剂： 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline Solubility: ≥ 10 mg/mL (33.75 mM); Clear solution 此方案可获得 ≥ 10 mg/mL (33.75 mM, 饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μ L 100.0 mg/mL 的澄清 DMSO 储备液加到 400 μ L PEG300 中，混合均匀；向上述体系中加入 50 μ L Tween-80，混合均匀；然后继续加入 450 μ L 生理盐水定容至 1 mL。																
2.请依序添加每种溶剂： 10% DMSO→ 90% (20% SBE- β -CD in saline) Solubility: ≥ 10 mg/mL (33.75 mM); Clear solution 此方案可获得 ≥ 10 mg/mL (33.75 mM, 饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μ L 100.0 mg/mL 的澄清 DMSO 储备液加到 900 μ L 20% 的 SBE- β -CD 生理盐水水溶液中，混合均匀。																	
3.请依序添加每种溶剂： 10% DMSO →90% corn oil Solubility: ≥ 10 mg/mL (33.75 mM); Clear solution																	

	<p>此方案可获得 $\geq 10 \text{ mg/mL}$ (33.75 mM, 饱和度未知) 的澄清溶液, 此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例, 取 $100 \mu\text{L}$ 100.0 mg/mL 的澄清 DMSO 储备液加到 $900 \mu\text{L}$ 玉米油中, 混合均匀。</p>
References	<p>[1]. <u>Sibhghatulla Shaikh, et al. Aptiom (Eslicarbazepine Acetate) as a Dual Inhibitor of β-Secretase and Voltage-Gated Sodium Channel: Advancement in Alzheimer's Disease-Epilepsy Linkage via an Enzoinformatics Study. CNS & Neurological Disorders Drug Targets Volume 13 , Issue 7 , 2014.</u></p>



源叶生物